EKEsra Kısacık

Esra Kısacık

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esra Kısacık has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The mediating role of emotion regulation skills in the relationship between childhood maltreatment and nicotine dependence

    by Esra Kısacık, Büşra Altınışık

    Nicotine dependence is one of the most common forms of addiction worldwide. Understanding the factors contributing to the initiation and maintenance of smoking behavior is crucial for prevention and intervention strategies. Based on models suggesting that early adverse experiences may impair emotion regulation and increase vulnerability to addictive behaviors, this study examined the mediating role of emotion regulation skills in the relationship between childhood maltreatment and nicotine dependence. The sample consisted of 132 university students aged 18–25 years. Participants completed the Demographic Information Form, the Childhood Trauma Questionnaire, the Fagerström Test for Nicotine Dependence, and the Emotion Regulation Skills Questionnaire, and their carbon monoxide (CO) levels were measured using the Pico+ Model Smokerlyzer device. Statistical analyses were conducted using SPSS, including Pearson correlation analyses and mediation analysis via the PROCESS Macro (Model 4). Correlation analyses revealed a negative association between childhood maltreatment and emotion regulation skills; however, no significant relationship was found between childhood maltreatment and nicotine dependence, nor between emotion regulation skills and nicotine dependence. Moreover, emotion regulation skills did not mediate the relationship between childhood maltreatment and nicotine dependence. The lack of support for the proposed mediation model suggests that emotion regulation may not be a central explanatory mechanism in this relationship within a relatively small and homogeneous sample of young adults aged 18–25, thereby highlighting the need to identify alternative pathways underlying nicotine dependence.

  • Serum Galectin‐1 and Galectin‐3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder

    by Büşra Sultan Sevindik, Özlem Olguner Eker, Akif Asdemir, Esra Kısacık, Ayşe Işık, Eser Kılıç, Ertuğrul Eşel

    Objective: Neuroinflammation is increasingly recognized as a key mechanism in the pathophysiology of Major Depressive Disorder (MDD). Galectin‐1 and Galectin‐3, β ‐galactoside‐binding lectins involved in immune regulation and neuroprotection, may serve as biomarkers linking inflammation to cognitive dysfunction. However, no previous study has simultaneously examined serum levels of these galectins alongside detailed cognitive assessments in MDD. This study aimed to determine whether Galectin‐1 and Galectin‐3 are altered in MDD and to explore their association with disease severity and cognitive performance. Method: Forty patients with MDD and 40 matched healthy controls were assessed. Depressive and anxiety symptoms were measured using the Hamilton Depression (HAM‐D) and Anxiety (HAM‐A) Rating Scales. Cognitive performance was evaluated with the Rey Auditory Verbal Learning Test, Go/No‐Go Test, and Stroop Test. Serum Galectin‐1, Galectin‐3, Glomerular Filtration Rate (GFR), and C‐reactive protein (CRP) levels were determined. Results: Serum Galectin‐1 and Galectin‐3 levels were significantly lower in the MDD group compared to controls ( p < 0.05). Galectin‐1 levels showed a negative correlation with HAM‐D and HAM‐A scores, indicating an inverse association with symptom severity (i.e., lower Galectin‐1 levels were associated with higher symptom severity). Patients exhibited impaired verbal learning, while no significant group differences were found in Go/No‐Go or Stroop performance. Galectin levels did not correlate with any cognitive test scores. Conclusion: Reduced Galectin‐1 and Galectin‐3 levels in MDD support their involvement in neuroinflammatory mechanisms. The inverse association between Galectin‐1 and symptom severity suggests that Galectin‐1 may be associated with symptom severity; however, the direction of this relationship remains unclear. The lack of associations with cognitive performance implies that cognitive deficits in MDD may be mediated by other immunometabolic pathways. These findings highlight galectins as promising but complex biomarkers, warranting further investigation in larger and longitudinal studies.